Enzo Biochem, Inc.
Enzo Biochem, Inc. (ENZB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
enzb · pe ratio · data through Jul 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Enzo Biochem, Inc. (ENZB) measures how much investors pay for each dollar of the company's trailing earnings. ENZB's current PE ratio of N/A is calculated by dividing its stock price of $0.70 by its TTM earnings per share of -$0.08.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-07-31
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 4 fiscal years · Front-end computedMinQ1 · 25%26.4x
MedianQ3 · 75%178.4x
Max
At N/A, ENZB's current P/E is lower than in 0% of its annual fiscal year readings over the past 4 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Enzo Biochem, Inc.You ENZB | $37M | N/A | — | -$0.08 |
 Alpha Cognition Inc. ACOGF | $36M | N/A | — | -$0.15 |
 China Shineway Pharmaceutical Group Limited CSWYY | $36M | 0.28x | — | $489.31 |
 Small Pharma Inc. DMTTF | $38M | N/A | — | -$0.07 |
 IntelGenx Technologies Corp. IGXT | $30M | N/A | — | -$0.06 |
 MedPeer,Inc. MDPEF | $43M | N/A | — | — |
 Mauna Kea Technologies S.A. MKEAF | $26M | N/A | — | -$0.16 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-07-31Latest FY2024 | — | $-0.51 | — | |
2023-07-31 FY2023 | 3.59x | $0.41 | — | |
2022-07-31 FY2022 | — | $-0.46 | — | |
2021-07-31 FY2021 | 45.87x | $0.07 | — | |
2020-07-31 FY2020 | — | $-0.71 | — | |
2019-07-31 FY2019 | — | $-2.09 | — | |
2018-07-31 FY2018 | — | $-0.22 | — | |
2017-07-31 FY2017 | — | $-0.05 | — | |
2016-07-31 FY2016 | 6.85x | $0.98 | — | |
2015-07-31 FY2015 | — | $-0.05 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Enzo Biochem, Inc. (ENZB) measures how much investors pay for each dollar of the company's trailing earnings. ENZB's current PE ratio of N/A is calculated by dividing its stock price of $0.70 by its TTM earnings per share of -$0.08.
Frequently asked questions
ENZB pe ratio · 6 questionsENZB's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.70 and TTM EPS of -$0.08. Data sourced from Financial Modeling Prep via ENZB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Enzo Biochem, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08